LifeStance Health Gr Q1 2024 GAAP EPS $(0.06) Beats $(0.08) Estimate, Sales $300.437M Beat $298.991M Estimate
Portfolio Pulse from Benzinga Newsdesk
LifeStance Health Gr (NASDAQ:LFST) reported Q1 2024 earnings with a smaller loss per share of $(0.06) compared to the $(0.08) estimate, and sales of $300.437M, surpassing the $298.991M estimate. This represents a 33.33% decrease in losses per share and an 18.94% increase in sales compared to the same period last year.

May 09, 2024 | 10:05 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
LifeStance Health reported a smaller-than-expected Q1 2024 loss and higher sales, indicating strong performance and growth.
Beating both earnings and sales estimates typically leads to positive investor sentiment and can result in a short-term stock price increase. The significant improvement in losses and sales growth compared to the previous year further strengthens the case for a positive impact on LFST's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100